Boost.ai Named as a Challenger in 2023 Gartner® Magic Quadrant™ for Enterprise Conversational AI Platforms
9.3.2023 19:01:00 EET | Business Wire | Press release
Boost.ai, a leading conversational AI platform, today announced it has been recognized as a Challenger by Gartner in their 2023 Magic Quadrant for Enterprise Conversational AI Platforms. For the second consecutive year, Boost.ai has been recognized in this Magic Quadrant by Gartner for its Ability to Execute and Completeness of Vision. We believe being recognized as a Challenger reinforces the company’s strength and leadership within the conversational AI space, as it continues to expand its technology and support a growing roster of clients across the globe.
The report states that “Gartner defines the enterprise conversational AI platform market as the market for software platforms used to build, orchestrate, and maintain multiple use cases of modalities of conversational automation.” As expectations for quality customer service continue to rise globally, Boost.ai has refined its technology, deploying industry-leading virtual agents that scale to meet the requirements of enterprise organizations. Boost.ai’s solution is powered by conversational AI, and the platform allows customers to scale up individually to thousands of industry-specific intents, enabling these businesses to effectively manage a very broad scope of customer queries in a matter of weeks in virtually any industry. With consistent 90% resolution rates, the solution facilitates immediate responses with accuracy, while its no-code conversation builder and AI trainer program allow customers to self-service their virtual agents and easily deploy service flows in response to customer feedback.
“Customer experience and digital transformation continue to be a priority, and I’m proud to say we have executed on this priority at Boost.ai. Over the last year, we’ve set customers up for success with our easily adaptable and scalable technology, and have solidified ourselves as world leaders in delivering the best possible customer experience for clients,” said Jerry Haywood, CEO of Boost.ai. “From my perspective, our placement in the 2023 Gartner Magic Quadrant is a testament to the work our team has done to perfect our solution and expand our existing offers based on new trends and technology.”
We believe this latest Magic Quadrant report encapsulates a strong previous year for Boost.ai, in which the company announced multiple customer wins and partnerships in the US and UK including Aspire Insurance, Metrobank, CallMiner, and Clarasys. The company also appointed Jerry Haywood as the new CEO, bringing 20 years of enterprise technology experience. With a conversational AI platform that delivers unlimited scalability as its central offering, Boost.ai is now leveraging its technology to tackle a new AI frontier: large language models (LLMs). Boost.ai combines the generative capabilities of LLMs like GPT-3, with company data to optimize their virtual agents for improved accuracy and brand alignment. As these models continue to develop, Boost.ai is working to ensure the technology can be properly integrated to offer the most advanced enterprise solution possible for both chat and voice.
"It’s an exciting time to be in the conversational AI space as the technology has taken another leap forward with the recent advancement of powerful LLMs. We think Future Gartner Magic Quadrant reports in this category could very well be defined by how well providers respond to this trend. We’re confident that we’re integrating the tech in a way that increases efficiency and performance, but most importantly is brand safe for our customers," said Lars Ropeid Selsås, Founder of Boost.ai. “I'm excited to see the massive amount of improvement our team and solution made in just one year, and now we can set our sights on solidifying our position in the market even further."
Boost.ai continues its upward global trajectory within the Enterprise Conversational AI market. The Boost.ai platform will focus on continuing to innovate and stay at the forefront of helping enterprise organizations to deliver exceptional customer experiences.
To learn more about how Boost.ai is empowering customers like DNB and Aspire Insurance using conversational AI, please visit: https://www.boost.ai/.
Gartner Disclaimer:
GARTNER is a registered trademark and service mark of Gartner Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005516/en/
Contact information
Jon Burch
Boost.ai@resonancecrowd.com
+44 208 819 3170
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom